Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PPHM THE COMPANY WILL SUCCEED IN LICENSING BAVI AND US PATIENT BUT FRUSTRATED INVESTORS WILL GO ALONG FOR THE RIDE!
Well stated CP
AFT HR 16:17 $ 1.26 High 504,447
Excellent post! Thanks
I prayerfully hope all the best for you Sir.
The anticipation is growing week by week as we approach that seminal moment of reality when he receive the PR that Bavi works and quite well! IMO
DIA Spot on enough said.
Bavi is coming into focus for a BLA. Dr. Garnick is the head on regultory, approved FDA fast track Phase 3,153 research sites around the world, KOL's endorsements and Avid expansion, to touch a on a few evidences of things to come. IMO
Habits of the investors are very unpredictable which is part and parcel for a speculative stock until it is no longer so speculative.
Correction from previous post. My brother-in-law a managing director of a large investment firm located in Orange county had spoken with Avid personal regarding their expansion and will be attending the event below. His impression was the expansion was pivoted more towards anticipated FDA approval of Phase 3 trail.
IBC's Biopharmaceutical Development & Production Week
March 30, 2015 - April 2, 2015
Location: Hyatt Regency Huntington Beach Resort & Spa--Huntington Beach, CA
Took advantage of the fears, rumors and conspiracy theories and added more shares to my position. Bargain prices. GLTA
Perhaps Cramer can put a good word in for us next week to move the PPS needle north for real. Instead of the false alarm tweets.
Luke Murray @EliteDayTraders 1/8/15
$PPHM hearing it may be on Cramers list tonight
two nods and a wink for sure.
Black Rock bought a lot of Apple way back in the day when most folks thought it was a fruit vendor. They have a pension for getting it right more often than not. Hence their share price.
The board appears to be a little in active this morning. I think my son's 100 share order filled this morning. LOL Buying some more because the PPS is a bargain price.
There is some meat in those potatoes. Your comments have validity. However, in spite of management's inconsistencies the science will prevail. IMO
Most BIO investors know this going in, thus timing of acquisition of shares can help those most critical of process. You buy in early just know these dilutions and reverse splits are part of the process.That of-coarse does not mean we have to like it.
You pegged it!
In that time window of opportunity such arguments can surface but will in general only influence the less informed.
BIO, I live just South of Washington DC in Northern Virginia. I have an acquaintance friend who will be attending. I hope to glean some information from his feedback as it relates to PPHM'S oncology space.
Agreed, If you invest in something after your due diligence strive to nurture the reason why you invested in it in the first place by continuing to support it. The chances are you will be better off.
CP Good summation. Thanks. I am a Long time investor from 1998. Still own a lot of shares. Looking ahead as always.
Well maybe I'll be buying a few more shares to shore up my share count. I Like the articles MD1225 has written in Seeking Alpha. Who said no mas. Eating those words already. PPHM drawing me in for more shares to own.
Jeff, had the same inclination to continue to buy. Once held 112,000 shares. Sold down to 50,000 then added 2000 more recently. This time I am stopping at 52000 shares. No mas!
Dilution lowers our share value but may be the bridge to our success
in moving share value over time. Fuzzy math I know.
I vote a (1). However, P3 FDA approval is a real possibility to consider.
I'm optimistic so I have a small fortune invested in this stock.
The science is centered in the new paradigm shift. Secondly and not exclusively my due diligence points me to this primary focal point. The back ground,experience and reputation of the man below.
Head of Regulatory Affairs
Dr. Garnick has over 30 years of experience in drug and biologic pharmaceutical development. He was formerly the Senior Vice President of Regulatory, Quality and Compliance at Genentech, Inc. Dr. Garnick spent 24 years at Genentech helping to found the biotechnology industry. While at Genentech Dr. Garnick was responsible for the approval of over 17 drugs, biologics and medical devices. He has extensive experience in analytical methodology, process validation, the regulatory review process both in the US and Europe and in Risk assessments. He has authored numerous scientific papers and has given numerous keynote presentations to the pharmaceutical Industry.
Approval is on the way. I am banking on it.
I added more shares to my position today. The only positive for me on the lower SP movement. Have enough shares now so let's move the needle north.
In the end I do not care if SK quacks like a duck as long as the science prevails and LONGS are rewarded for their patients or lack there of.
My wife says PPHM isn't going nowhere. I am wasting my time in vesting in PPHM. Well when this thing takes of she's going to the DOGHOUSE. She said if it does go big she'll go to the doghouse for one night. HMM.... I wander if I should take her up on that. Best not.
The two primary reasons for me buying and holding PPHM relate to
DR Robert Garnick's back ground and experience and bavi's potential.
In 10-2009, Dr. Robert Garnick joined Peregrine as Head/Regulatory ( http://tinyurl.com/yga7z4x ). In his 24 years at Genentech (1984-2008; from Feb'01-Oct'08 as Senior V.P. of Regulatory, Quality & Compliance), he was responsible for 17 new product approvals, including most of DNA's top selling monoclonal antibody therapeutics such as Rituxan, Herceptin, Avastin, and Lucentis. He was responsible for all the regulated aspects of Genentech's business, including drug development, commercial production, and promotional & labeling compliance.
and
• On 7-16-12, Dr. Robert Garnick said this about the ongoing Bavi+Doce randomized 2nd-Line NSCLC Ph.2B n=121 trial (which is going to double+ MOS vs. Doce ctl-arm): "I've seen a lot of Ph2 & Ph3 data, and this is as compelling Ph2 data as I've ever seen. So, I'm very comfortable proposing an [EOP2] meeting with the FDA for Q4'12."
Yes,I would say a toxic viewpoint from good ole Adam F.
Care to add up how often he misses the mark on his predictions?
Too many.
15. Peregrine Pharma (PPHM) manages to enroll seven patients into its bavituximab Phase III lung cancer trial, but that's five more than Cel-Sci (CVM) manages to enroll in the Multikine head-and-neck cancer study.
Remember when someone cared about bavituximab? Neither can I.
I am familiar with some of the operations at Motfley Fool Headwaters in Alexandria Virginia. This article was cranked out lacking updated information and it was not due to research laziness. There is an agenda. I'll add IMO.
Final persuasive point.
According to the dictionary. When the adjective "coming" is applied to the noun "year" it implies following or impending; next; approaching: the coming year.
Again forward looking statements can be interpreted various ways depends on your views and discernment.
Now getting back to a point I was trying to make earlier.
Now what is important to note in my view, was the level of interest on potential partnership deals before the issues became apparent on Phase 2.
Now juxtapose those that were interested then with the current Fast Track Phase 3 Sunrise trial. Certainly, many of those companies are paying attention and are still in the picture.
They have not all left the bleachers.
Eureka! The moment of clarification has surfaced. The coming year is the one coming. Makes since. Although forward looking statements can be deciphered multiple ways depends on the listener. I know one thing for certain we all want results.
Jimsgtx,
You made my point very clear thank you. I was speaking in context of that PR and the Phase 2 issues affecting those possible partnership developments from occurring during that time frame. Obviously were in 2015. Hopefully Phase 3 will rekindle new partnership developments.
Frustrated,
This PR came out prior to Phase 2 issues as I understand and there would naturally be a paradigm shift n partnering developments in lieu of this. Hopefully, Phase 3 Sunrise will bring this back into the fold and your frustration will diminish.
Noticed in reading some of the older PR'S it seems prior to the Phase 2 issues PPHM was on the heals of partnering: Hopefully Phase 3 Sunrise will bring these discussions back into the arena.
7-16-12 CEO Steve King, QtlyCC ( http://tinyurl.com/cs7spbz )
......"The strength of this 2nd-Line NSCLC data (esp. MOS trends) in this large area of high unmet medical need has also sparked a surge in partnering discussions that has included over 15 in-person partnering meetings since that time with major players in oncology, with all discussions ongoing and addl. parties showing interest. Our goal for the program is to position ourselves, along with a potential partner, to initiate Ph3 by mid-2013, which means an EOP2 meeting by yr-end'12. It would be ideal to have a partner on board to participate in the EOP2 meeting, and we have communicated this to interested parties and they agree."
Happy New Year board members. My New Years resolution: The PPS rises toward these wonderful numbers between $8-$15 before next New Years. I believe most of you would be happy with these numbers or better.
(It sure would be nice to hear about how the stock exploded upwards because of ……….?)
FDA approval of Phase 3 Sunrise should do it. Question though? When? Speculation indicates possibly sometime during event driven look-in's? Conservative view points may point towards end of trail in 2016. I say, if the read outs on MOS is above SOC at some meaningful level it would suggest an "unmet need" criteria on SOC for a BLA.
Happy New year to all.
Personally I am very optimistic about the oncology space PPHM is in
considering the science with respect to PS and am looking forward to the results of phase 3 Sunrise trial. I consider the other trails as supportive data to assist in bringing this into fruition.
Obviously, these other trails will provide essential data for future events. The liver trial results I consider in this same category as supportive for Phase 3 trail. I would love to be wrong on the liver trial though and consider what many are claiming as possibility for partnership to meet unmet need. Enjoy reading all view points on this board but in particular information that fosters my views and expectations of success.
GLTA LONGS HAPPY NEW Year to all!